BR112019002058A2 - composição injetável de ibuprofeno estável - Google Patents

composição injetável de ibuprofeno estável

Info

Publication number
BR112019002058A2
BR112019002058A2 BR112019002058-6A BR112019002058A BR112019002058A2 BR 112019002058 A2 BR112019002058 A2 BR 112019002058A2 BR 112019002058 A BR112019002058 A BR 112019002058A BR 112019002058 A2 BR112019002058 A2 BR 112019002058A2
Authority
BR
Brazil
Prior art keywords
composition
ibuprofen
injectable composition
stable ibuprofen
stable
Prior art date
Application number
BR112019002058-6A
Other languages
English (en)
Inventor
Jamil Irfan
Original Assignee
Ambah Ip Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambah Ip Limited filed Critical Ambah Ip Limited
Publication of BR112019002058A2 publication Critical patent/BR112019002058A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

a presente invenção se refere a uma composição para formulação injetável, a composição compreendendo: - uma solução aquosa de ibuprofeno e arginina com uma razão molar de ibuprofeno:arginina compreendida entre 1:1,1 e 1:2,1; - uma solução aquosa de um composto diurético compreendendo entre 3,9% e 4,35% p/v do composto diurético. a presente invenção também se refere a uma composição farmacêutica compreendendo a dita composição e ao uso da dita composição e da dita composição farmacêutica.
BR112019002058-6A 2016-08-02 2017-07-27 composição injetável de ibuprofeno estável BR112019002058A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PK468/2016 2016-08-02
PK4682016 2016-08-02
PCT/IB2017/054556 WO2018025128A1 (en) 2016-08-02 2017-07-27 Stable ibuprofen injectable composition

Publications (1)

Publication Number Publication Date
BR112019002058A2 true BR112019002058A2 (pt) 2019-05-07

Family

ID=59699972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002058-6A BR112019002058A2 (pt) 2016-08-02 2017-07-27 composição injetável de ibuprofeno estável

Country Status (10)

Country Link
US (1) US11541024B2 (pt)
EP (1) EP3493788A1 (pt)
JP (2) JP7386080B2 (pt)
KR (1) KR102387287B1 (pt)
CN (1) CN109843266B (pt)
AU (1) AU2017307313B2 (pt)
BR (1) BR112019002058A2 (pt)
CA (1) CA3032493C (pt)
MX (1) MX2019001344A (pt)
WO (1) WO2018025128A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056261A (zh) * 2018-12-14 2021-06-29 费森尤斯卡比奥地利有限公司 包含布洛芬和磷酸盐缓冲剂的用于肠胃外施用的药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932829C1 (pt) * 1989-09-30 1991-05-02 Ciba-Geigy Ag, Basel, Ch
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
DE60114249T2 (de) * 2001-11-02 2006-05-18 Cumberland Pharmaceuticals Inc., Nashville Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
US8652456B2 (en) * 2004-06-21 2014-02-18 Basf Se Aqueous preparations comprising at least one water-soluble or water-dispersible copolymer with cationgenic groups
AR052469A1 (es) * 2005-01-28 2007-03-21 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido
US7785624B2 (en) 2006-03-02 2010-08-31 Inspire Pharmaceuticals, Inc. Pharmaceutical latrunculin formulations
CN101069681A (zh) * 2006-05-10 2007-11-14 汪洪湖 含有布洛芬的注射剂及其制备方法
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
CN102335114B (zh) * 2010-07-23 2015-07-15 重庆医药工业研究院有限责任公司 一种稳定的布洛芬精氨酸注射剂及其制备方法
HUE028045T2 (en) * 2012-02-20 2016-11-28 Pharmaceutical Solutions Ind Ltd Intravenous ibuprofen infusion
ES2422563B1 (es) * 2012-03-08 2014-06-10 Farmalider S.A. Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
CA2881192A1 (en) * 2012-08-09 2014-02-13 Nestec S.A. Anthocyanin colouring composition
CN103284985A (zh) * 2013-05-20 2013-09-11 北京阜康仁生物制药科技有限公司 稳定的(S)-α-甲基-4-（2-甲基丙基）苯乙酸药物组合物
CN103301118A (zh) * 2013-06-27 2013-09-18 海南卫康制药(潜山)有限公司 注射用精氨酸布洛芬组合物
WO2016008546A1 (en) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen

Also Published As

Publication number Publication date
CN109843266B (zh) 2023-08-11
AU2017307313A1 (en) 2019-02-28
MX2019001344A (es) 2019-08-29
EP3493788A1 (en) 2019-06-12
WO2018025128A1 (en) 2018-02-08
KR102387287B1 (ko) 2022-04-14
US20190183823A1 (en) 2019-06-20
JP2022089867A (ja) 2022-06-16
US11541024B2 (en) 2023-01-03
CA3032493A1 (en) 2018-02-08
JP7386080B2 (ja) 2023-11-24
JP2019523292A (ja) 2019-08-22
CA3032493C (en) 2022-07-05
AU2017307313B2 (en) 2021-09-09
KR20190062385A (ko) 2019-06-05
CN109843266A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2015002330A1 (es) Análogo de insulina novedoso y su uso.
CO2018002026A2 (es) Composiciones de insulina de rápida acción
BR112013016770A2 (pt) formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica
AR098168A1 (es) Formulación estable de insulina glulisina
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
UY35848A (es) Tienopirimidinas
NI201600006A (es) Pirazolo-piridinaminas sustituidas
UY37488A (es) Novedosas formulaciones de compuestos de beta-lactama sustituidos con amidina sobre la base de ciclodextrinas modificadas y agentes acidificantes, su preparación y uso como composiciones farmacéuticas antimicrobianas
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
BR112016006963A2 (pt) composição farmacêutica
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
EA201990093A1 (ru) Двухкомпонентная композиция
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112019002058A2 (pt) composição injetável de ibuprofeno estável

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]